谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Ritlecitinib, an oral dual JAK3/TEC family kinase inhibitor, induces differential changes in immunological protein levels across Fitzpatrick skin types (FST) in patients with active nonsegmental vitiligo (NSV)

E. Peeva,Y. Yamaguchi,Z. Ye,B. King,M. Picardo,A. Sloan,K. Ezzedine,E. Del Duca,Y. Estrada,M. Hassan-Zahraee,W. He,C. Hyde,J. Bar,P. Facheris,E. Guttman-Yassky

Journal of Investigative Dermatology（2023）

引用 0|浏览30
暂无评分
关键词
active nonsegmental vitiligo,oral dual jak3/tec,jak3/tec family kinase inhibitor,ritlecitinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要